David M. Goldstein

Chief Tech/Sci/R&D Officer at PRINCIPIA BIOPHARMA INC.

58 year

Health Technology

Consumer Services

Profile

David M.
Goldstein is currently the Director at Frontier Medicines Corp.
and the Chief Scientific Officer at Principia Biopharma, Inc. He previously worked as the Senior Director-Medicinal Chemistry at Roche Holding AG from 1994 to 2011.
He also worked as a Professor at Stanford University.
Goldstein holds a doctorate degree from the University of Virginia and an undergraduate degree from Franklin & Marshall College.

David M. Goldstein active positions

Companies	Position	Start
PRINCIPIA BIOPHARMA INC.	Chief Tech/Sci/R&D Officer	31/12/2015
Frontier Medicines Corp. Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.	Director/Board Member	29/03/2021

All active positions of David M. Goldstein

Former positions of David M. Goldstein

Companies	Position	End
ROCHE HOLDING AG	Corporate Officer/Principal	31/12/2010
Stanford University	Corporate Officer/Principal	-

See the detail of David M. Goldstein's experience

Training of David M. Goldstein

University of Virginia	Doctorate Degree
Franklin & Marshall College	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David M. Goldstein's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ROCHE HOLDING AG	Health Technology

Private companies	2
Principia Biopharma, Inc. Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.	Health Technology
Frontier Medicines Corp. Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Frontier Medicines Corp. develops medicines that redefine the course of debilitating diseases. The company was founded by Chris Varma, Daniel K. Nomura and Roberto Zoncu in 2018 and is headquartered in South San Francisco, CA.	Health Technology